top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance

18/03/2026
























Idience's venadaparib received the FDA fast track designation for gastric cancer (Ref)


The US FDA granted the fast track designation to Idience's venadaparib (PARP inhibitor) for the treatment of gastric cancer.


  • Lee Won-sik, CEO, Idience: “This Fast Track designation is highly meaningful in that the FDA has recognized Venadaparib’s clinical potential and its ability to help address unmet medical needs. We will do our utmost to accelerate our global clinical development and deliver a new treatment option.”




Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page